Sanfran, good points.

I did a post on SH about recent developments. I was very disheartened by the RVX and Zenith updates by Don a few months back. I was not at all bothered by the scientific potential. I remain long and I strongly believe that apabetalone (rvx-208) is going to be a blockbuster and particularly in the context of CEPT inhibitors which so far have raised HDL significantly and had ZERO impact on MACE events. They failed! We already know the apabetalone reduced MACE by 55% in 6 months!!! It strikes me that BET inhibition particularly using the scaffold that RVX uses is a very powerful pathway. I'm starting to believe Don when he says RVX has an 8 year lead on this science.

Remember, the the BET inhibitor science is also the platform for the Zenith compounds. If the prostate trial shows early promise for zen3694 it will accelerate credibility of apabetalone and the entire Resverlogix and Zenith platforms. Remember Don stated in the restruring of Zenith into Zenith Epigenetics and Zenith Capital that he would accept one cheque (RVX) of two (Zenith plus RVX). If BP or Eastern or NGN or another capital company sees the potential we'll see an excellent payout long before BETonMACE is complete.

I was disheartened because I felt it was going to be a 2 year wait until BETonMACE findings were released and hence lots of time to sit back and watch the grass grow. However, we have the "futility" results coming up. If the trial continues we are in gold! We have the orphan trial. We have regional deals coming up. We have a company in RVX that now has downstream potential, for example, with Hepalink China, Macau, Taiwan and thier USA division.

Many events have accelerated far faster than I expected...2 new board appointments and hiring the VP of Investor Relations to name a couple.

The momentum is interest is growing far faster than I expected and why would Don hire a VP of Investro Relations at this time?

IMHO GLTA

Cheers :)

Toinv